Charles River Laboratories International, Inc. (NYSE:CRL) Shares Acquired by MJP Associates Inc. ADV

MJP Associates Inc. ADV boosted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 27.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,036 shares of the medical research company’s stock after buying an additional 1,300 shares during the quarter. MJP Associates Inc. ADV’s holdings in Charles River Laboratories International were worth $1,247,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in Charles River Laboratories International in the fourth quarter worth approximately $101,319,000. Point72 Asset Management L.P. increased its holdings in Charles River Laboratories International by 499.1% in the fourth quarter. Point72 Asset Management L.P. now owns 368,984 shares of the medical research company’s stock valued at $87,228,000 after buying an additional 307,398 shares during the last quarter. Meritage Group LP raised its stake in Charles River Laboratories International by 30.8% in the fourth quarter. Meritage Group LP now owns 1,155,376 shares of the medical research company’s stock valued at $273,131,000 after buying an additional 271,743 shares in the last quarter. Epoch Investment Partners Inc. lifted its holdings in Charles River Laboratories International by 2,733.4% during the 1st quarter. Epoch Investment Partners Inc. now owns 247,501 shares of the medical research company’s stock worth $67,060,000 after buying an additional 238,766 shares during the last quarter. Finally, KBC Group NV boosted its position in shares of Charles River Laboratories International by 5,003.9% during the 4th quarter. KBC Group NV now owns 215,639 shares of the medical research company’s stock worth $50,977,000 after acquiring an additional 211,414 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Argus reiterated a “hold” rating on shares of Charles River Laboratories International in a research note on Friday, June 28th. UBS Group cut their target price on Charles River Laboratories International from $290.00 to $240.00 and set a “buy” rating on the stock in a research report on Thursday. The Goldman Sachs Group decreased their target price on Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating for the company in a research report on Thursday. JPMorgan Chase & Co. lowered Charles River Laboratories International from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $270.00 to $205.00 in a research report on Thursday. Finally, Robert W. Baird cut shares of Charles River Laboratories International from an “outperform” rating to a “neutral” rating and cut their target price for the company from $239.00 to $191.00 in a report on Thursday. Ten investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $232.79.

Charles River Laboratories International Trading Down 0.5 %

CRL traded down $0.96 during trading on Friday, hitting $200.97. The company’s stock had a trading volume of 1,060,174 shares, compared to its average volume of 581,319. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $275.00. The firm’s 50 day moving average price is $214.99 and its 200-day moving average price is $231.41. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.75 and a quick ratio of 1.37. The stock has a market cap of $10.35 billion, a PE ratio of 23.64, a PEG ratio of 2.32 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.05 by $0.22. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $997.24 million. On average, analysts expect that Charles River Laboratories International, Inc. will post 10.99 earnings per share for the current year.

Charles River Laboratories International declared that its Board of Directors has authorized a stock repurchase program on Wednesday, August 7th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 9.6% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s management believes its stock is undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).